Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

RTI Biologics Gets 510(k) Clearance From FDA For Porcine Dermis Implant

RTI Biologics Inc. (RTIX: Quote), a provider of orthopedic and other biologic implants, said has received 510(k) clearance from the U.S. Food and Drug Administration or FDA for its porcine dermis implant. The implant is planned for use in soft tissue repair procedures such as hernia repair.

Stored hydrated and ready-to-use, the porcine dermis implant consists of non-crosslinked porcine dermis, designed to act as a scaffold that allows for neovascularization and reincorporation with the patient's own tissue.

The implant, would be made available in various shapes and sizes, is sterilized through the Tutoplast Tissue Sterilization Process, a chemical process to sterilize and preserve tissue for implantation. Since the first clinical use in 1971, there has been zero incidence of implant-associated infection from millions of implants sterilized through the process.

The company added that the implants would be processed at RTI's facility in Neunkirchen, Germany for commercial distribution in the U.S. later this year. The facility has been validated for processing and has begun production of the implants.

Click here to receive FREE breaking news email alerts for RTI Surgical Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.